Bristol Revs Its R&D Engine: An Interview with Elliott Sigal and Francis Cuss

Just one year ago, Bristol-Myers Squibb's days as an independent entity seemed numbered. But thanks to the resolution of the Plavix crisis, innovative deal-making, and an R&D pipeline surging with specialty-focused products, the company is now thriving. In a free-wheeling Q&A, Bristol's R&D gurus, Francis Cuss and Elliott Sigal, discuss the need for a new kind of biopharma that is specialty-focused and technology agnostic.